openPR Logo
Press release

BioFocus and InterMed Discovery announce Marketing Collaboration

07-25-2011 08:21 AM CET | Science & Education

Press release from: Biofocus

/ PR Agency: Alto Marketing
BioFocus, an integrated drug discovery service partner, and InterMed Discovery GmbH (IMD), a natural product lead-discovery company, today announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed.

Under the terms of the collaboration, IMD will make its natural product screening libraries available and provide follow-on services to BioFocus. BioFocus will then incorporate these as part of its own integrated drug discovery offerings. BioFocus has a track record of service deals with industry for the discovery of active ingredients in pharmaceutical, animal health and agrochemical applications.

“We believe that the combination of our natural product capabilities with the well known discovery capabilities of BioFocus will offer a powerful discovery solution at a time when there is already growing demand from the pharma, veterinary and agro industries to fill depleted pipelines,“ said Dr. Thomas Henkel, co-Managing Director of InterMed Discovery.

“We have been impressed with the scale of IMDs natural product discovery capabilities and we believe that when InterMed’s natural product libraries and services are combined with our screening services, our engine for drug discovery will be substantially enhanced and more cost-effective for our clients,” added Dr. Chris Newton, Managing Director BioFocus.

Originally developed within Bayer Healthcare AG, the IMD natural product integrated discovery platform consists of the largest natural compound libraries available to industry and a powerful combination of rich databases of data and research relating to natural compounds. Together with BioFocus’ screening technologies and integrated discovery capabilities they amount to a strong platform in the discovery of biologically functional natural compounds.

About BioFocus
BioFocus delivers drug discovery solutions through a comprehensive platform run by dedicated teams with a track record in gene-to-clinical candidate discovery. BioFocus’ offering includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry and ADME/PK services, supported by unique chemogenomic and informatics tools. As a service division of Galapagos, BioFocus has over 210 employees with research facilities in three countries. For more information visit www.biofocus.com.

About InterMed Discovery
InterMed Discovery is a world class natural product lead-discovery company, driving innovation through the generation of novel product candidates for the life science, food and cosmetics industries. Using one of the most powerful validated natural product discovery engines, InterMed Discovery generates proprietary product pipelines of functional ingredients and also supports partners in research and lead generation. Biologically characterised product leads are identified using IMD BIOPROFILING® and NPSilico®, which together comprise a proprietary bioinformatics platform drawing on screening results compiled over many years, complemented by primary biological and chemical research on natural products. InterMed Discovery adds to this the industry’s largest collections of pure compounds, sample fractions and mixtures as its source for potential natural product leads. The Company is located in Dortmund, Germany and was founded in 2006 as a management buyout of the Natural Products Research Unit of Bayer Healthcare. IMD entered into strategic cooperations with companies such as Cognis GmbH (now BASF SE) and Biotropics Malaysia Berhad. Further information on InterMed Discovery can be found at www.intermed-discovery.com.

BioFocus® is a trademark of Galapagos NV and/or its affiliates © Copyright 2011 Galapagos NV.

Alto Marketing

Office 3 | Universal Marina | Crableck Lane | Sarisbury Green | Southampton | SO31 7AL

BioFocus media enquiries
Dr Paul Avery
Science Writer
Alto Marketing Limited
Phone: +44 1489 557 672
Email: paula@alto-marketing.com

BioFocus product enquiries
BioFocus
Phone: + 44 1799 533 500
Email: info@glpg.com
Internet: www.biofocus.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release BioFocus and InterMed Discovery announce Marketing Collaboration here

News-ID: 184584 • Views:

More Releases from Biofocus

Argenta and BioFocus announce two-year extension of drug discovery collaboration …
Galapagos NV (Euronext: GLPG) announced today that its service division Argenta has extended its integrated contract drug discovery agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). Total potential value of the contract extension is up to £21.5 million (€23.4 million). This is the third such extension since the agreement was announced in December 2005. The agreement covers a number of drug discovery
BioFocus enters collaboration with Michael J. Fox Foundation
BioFocus announced today that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease. Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson’s disease diagnostic test. “We are delighted to have the opportunity to support The Michael J.
BioFocus extends collaboration with Usher III Initiative
BioFocus announced today that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision. BioFocus and the Usher III Initiative began their collaboration in July 2010 with BioFocus performing an integrated drug discovery program encompassing medicinal chemistry, ADME and biological sciences, aiming at a
Astellas Pharma and BioFocus sign target discovery agreement
BioFocus announced today that it has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders. Under the agreement, BioFocus will utilize its SilenceSelect® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration. “We are delighted to support Astellas Pharma

All 5 Releases


More Releases for InterMed

Radiodermatitis Market Overall Study Report 2025-2032 | Intermed Pharmaceuticals …
New Report Highlights Key Insights in the Radiodermatitis Market (2025-2032) Radiodermatitis Market is estimated to be valued at USD 442.8 Mn in 2025 and is expected to reach USD 594.6 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 4.3% from 2025 to 2032. Coherent Market Insights has published a detailed report titled "Radiodermatitis Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032." This study offers a deep dive
Radiodermatitis Market Set to Witness Significant Growth by 2025-2032 | Intermed …
Latest Report, titled "Radiodermatitis Market" Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. The report features a comprehensive table of contents, figures, tables, and charts, as well as insightful analysis. The Radiodermatitis market has been expanding significantly in recent
Radiodermatitis Market Growth in Future Scope 2024-2031 | Intermed Pharmaceutica …
Radiodermatitis Market Trends Overview 2024-2031: A new Report by Coherent Market Insights, titled "Radiodermatitis Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Radiodermatitis market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. This report has a complete table of contents, figures, tables, and charts, as well as insightful analysis. The Radiodermatitis
Radiodermatitis Market Future Business Opportunities 2024-2031 | Acelity, Inc., …
The Latest research report on the Radiodermatitis Market 2024 provides a comprehensive analysis of the current market landscape, with forecasts extending to 2031. This study combines qualitative and quantitative insights to highlight significant market developments, challenges, competitive dynamics, and potential opportunities and trends shaping the Radiodermatitis Market. The report covers market size, recent trends, growth projections, market share, and development status. Additionally, it examines government policies, market dynamics, cost structures,
Radiodermatitis Market Size SWOT analysis and Key Business Strategies, Demand & …
Market Overview: Radiodermatitis refers to skin damage or irritation caused by radiation therapy. It is a common side effect of radiotherapy treatment for cancer patients. Products used in prevention and treatment of radiodermatitis include topical agents, dressings, and skin care products. Market Dynamics: The global radiodermatitis market is expected to witness significant growth owing to increasing incidence of cancer and rising use of radiotherapy for cancer treatment. According to WHO, cancer burden rose
Radiation Dermatitis Treatment Market by Trends, Dynamic Innovation in Technolog …
Radiation Dermatitis Treatment market report is one of the significant factors to help business players in getting all the required data and obtain a well perspective and detailed understanding of target customers. Creating an organizational plan becomes easy by referring this market research report to fulfill customer requirements. It points out problems in product offerings and allows solving those problems and generating larger profits. Knowing customers well greatly assists business